de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson’s disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:S21–3.
Assogna F, Pellicano C, Savini C, Macchiusi L, Pellicano GR, Alborghetti M, et al. Drug choices and advancements for managing depression in Parkinson’s disease. Curr Neuropharmacol. 2020;18:277–87.
Article CAS PubMed PubMed Central Google Scholar
Marinus J, Zhu K, Marras C, Aarsland D, van Hilten JJ. Risk factors for non-motor symptoms in Parkinson’s disease. Lancet Neurol. 2018;17:559–68.
Aarsland D, Påhlhagen S, Ballard CG, Ehrt U, Svenningsson P. Depression in Parkinson disease–epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35–47.
Bhome R, Zarkali A, Thomas GEC, Iglesias JE, Cole JH, Weil RS. Thalamic white matter macrostructure and subnuclei volumes in Parkinson’s disease depression. NPJ Parkinsons Dis. 2022;8:2.
Article CAS PubMed PubMed Central Google Scholar
Lenka A, Ingalhalikar M, Shah A, Saini J, Arumugham SS, Hegde S, et al. Hippocampal subfield atrophy in patients with Parkinson’s disease and psychosis. J Neural Transm (Vienna). 2018;125:1361–72.
Article CAS PubMed Google Scholar
Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, et al. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson’s disease. Psychosomatics. 2010;51:474–9.
CAS PubMed PubMed Central Google Scholar
Wang XM, Zhang YG, Li AL, Long ZH, Wang D, Li XX, et al. Relationship between levels of inflammatory cytokines in the peripheral blood and the severity of depression and anxiety in patients with Parkinson’s disease. Eur Rev Med Pharmacol Sci. 2016;20:3853–6.
Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science. 2012;338:68–72.
Article CAS PubMed PubMed Central Google Scholar
Roddy DW, Farrell C, Doolin K, Roman E, Tozzi L, Frodl T, et al. The Hippocampus in depression: more than the sum of its parts? advanced hippocampal substructure segmentation in depression. Biol Psychiatry. 2019;85:487–97.
Calabresi P, Castrioto A, Di Filippo M, Picconi B. New experimental and clinical links between the hippocampus and the dopaminergic system in Parkinson’s disease. Lancet Neurol. 2013;12:811–21.
Article CAS PubMed Google Scholar
Huang Y, Coupland NJ, Lebel RM, Carter R, Seres P, Wilman AH, et al. Structural changes in hippocampal subfields in major depressive disorder: a high-field magnetic resonance imaging study. Biol Psychiatry. 2013;74:62–8.
Györfi O, Nagy H, Bokor M, Moustafa AA, Rosenzweig I, Kelemen O, et al. Reduced CA2-CA3 Hippocampal subfield volume is related to depression and normalized by l-DOPA in newly diagnosed Parkinson’s disease. Front Neurol. 2017;8:84.
Article PubMed PubMed Central Google Scholar
Ballanger B, Klinger H, Eche J, Lerond J, Vallet AE, Le Bars D, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson’s disease. Mov Disord. 2012;27:84–89.
Article CAS PubMed Google Scholar
Mosser CA, Baptista S, Arnoux I, Audinat E. Microglia in CNS development: Shaping the brain for the future. Prog Neurobiol. 2017;149-150:1–20.
Woodburn SC, Bollinger JL, Wohleb ES. The semantics of microglia activation: neuroinflammation, homeostasis, and stress. J Neuroinflammation. 2021;18:258.
Article PubMed PubMed Central Google Scholar
Colonna M, Butovsky O. Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35:441–68.
Article CAS PubMed PubMed Central Google Scholar
Sawada M, Imamura K, Nagatsu T. Role of cytokines in inflammatory process in Parkinson’s disease. J Neural Transm Suppl. 2006;70:373–81.
Litvinchuk A, Wan YW, Swartzlander DB, Chen F, Cole A, Propson NE, et al. Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer’s disease. Neuron. 2018;100:1337–1353.e5.
Article CAS PubMed PubMed Central Google Scholar
Stephan AH, Barres BA, Stevens B. The complement system: an unexpected role in synaptic pruning during development and disease. Annu Rev Neurosci. 2012;35:369–89.
Article CAS PubMed Google Scholar
Stevens B, Allen NJ, Vazquez LE, Howell GR, Christopherson KS, Nouri N, et al. The classical complement cascade mediates CNS synapse elimination. Cell. 2007;131:1164–78.
Article CAS PubMed Google Scholar
Cong Q, Soteros BM, Wollet M, Kim JH, Sia GM. The endogenous neuronal complement inhibitor SRPX2 protects against complement-mediated synapse elimination during development. Nat Neurosci. 2020;23:1067–78.
Article CAS PubMed PubMed Central Google Scholar
Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352:712–6.
Article CAS PubMed PubMed Central Google Scholar
Schartz ND, Tenner AJ. The good, the bad, and the opportunities of the complement system in neurodegenerative disease. J Neuroinflammation. 2020;17:354.
Article PubMed PubMed Central Google Scholar
Crider A, Feng T, Pandya CD, Davis T, Nair A, Ahmed AO, et al. Complement component 3a receptor deficiency attenuates chronic stress-induced monocyte infiltration and depressive-like behavior. Brain Behav Immun. 2018;70:246–56.
Article CAS PubMed PubMed Central Google Scholar
Wang R, Wang QB, Xie T, Guo KH. The role of glial cell activation mediated by complement system C1q/C3 in depression-like behavior in mice. J SUN Yat-sen Univ (Med Sci). 2021;42:328–37.
Mazzocchio R, Caleo M. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system. Neuroscientis. 2015;21:44–61.
Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75:837–44.
Article CAS PubMed Google Scholar
Zhang Q, Wu W, Fan Y, Li Y, Liu J, Xu Y, et al. The safety and efficacy of botulinum toxin A on the treatment of depression. Brain Behav. 2021;11:e2333.
Article CAS PubMed PubMed Central Google Scholar
Luvisetto S. Botulinum neurotoxins in central nervous system: an overview from animal models to human therapy. Toxins (Basel). 2021;13:751.
Article CAS PubMed Google Scholar
Li Y, Liu J, Liu X, Su CJ, Zhang QL, Wang ZH, et al. Antidepressant-like action of single facial injection of botulinum neurotoxin A is associated with augmented 5-HT levels and BDNF/ERK/CREB pathways in mouse brain. Neurosci Bull. 2019;35:661–72.
Article CAS PubMed PubMed Central Google Scholar
Zhu C, Wang K, Yu T, Liu H. Effects of botulinum toxin type a on mood and cognitive function in patients with parkinson’s disease and depression. Am J Transl Res. 2021;13:2717–23.
CAS PubMed PubMed Central Google Scholar
Lyu A, Fan Y, Tang L, Guo X, Liu J, Huang Y, et al. Clinical study on the efficacy and safety of botulinum toxin A in the treatment of Parkinson′s disease with depression. Chin J Neurol. 2019;52:745–51.
Ham HJ, Yeo IJ, Jeon SH, Lim JH, Yoo SS, Son DJ, et al. Botulinum toxin A ameliorates neuroinflammation in the MPTP and 6-OHDA-induced Parkinson’s disease models. Biomol Ther (Seoul). 2022;30:90–97.
Article CAS PubMed Google Scholar
Antipova V, Holzmann C, Hawlitschka A, Witt M, Wree A. Antidepressant-like properties of intrastriatal botulinum neurotoxin-A injection in a unilateral 6-OHDA rat model of Parkinson’s disease. Toxins (Basel). 2021;13:505.
Article CAS PubMed Google Scholar
Cong Q, Soteros BM, Huo A, Li Y, Tenner AJ, Sia GM. C1q and SRPX2 regulate microglia mediated synapse elimination during early development in the visual thalamus but not the visual cortex. Glia. 2022;70:451–65.
Article CAS PubMed Google Scholar
Young K, Morrison H. Quantifying microglia morphology from photomicrographs of immunohistochemistry prepared tissue using ImageJ. J Vis Exp. 2018;136:57648.
Sanchez K, Darling JS, Kakkar R, Wu SL, Zentay A, Lowry CA, et al. Mycobacterium vaccae immunization in rats ameliorates features of age-associated microglia activation in the amygdala and hippocampus. Sci Rep. 2022;12:2165.
留言 (0)